Announcement from Zhejiang Shapuaisi Pharmaceutical Co., Ltd. on the postponement of reply to the inquiry letter from the Shanghai Stock Exchange
Securities code: 603168 Securities abbreviation: Shapuaisi Announcement number: Lin 2026-009 Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Announcement on Postponement of Reply to Shanghai Stock Exchange’s Inquiry Letter
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Inquiry Letter Regarding Matters Related to Zhejiang Shapuaisi Pharmaceutical Co., Ltd.'s Purchase of Assets from Related Parties" (hereinafter referred to as the "Inquiry Letter") issued by the Shanghai Stock Exchange (hereinafter referred to as the "Shanghai Stock Exchange") on March 17, 2026 (Shanghai Securities Official Letter [2026] No. 0514) (hereinafter referred to as the "Inquiry Letter"), requiring the company to receive the inquiry letter in 5 A written reply will be provided to the inquiry letter within 1 trading day. For details, please refer to the "Announcement on Receipt of the Inquiry Letter from the Shanghai Stock Exchange on Matters Related to Zhejiang Sap Aisi Pharmaceutical Co., Ltd.'s Purchase of Assets from Related Parties" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on March 18, 2026 (Announcement No.: 2026-008).
After receiving the inquiry letter, the company attached great importance to it and actively organized relevant personnel to respond to the issues involved in the inquiry letter one by one. As of the disclosure date of this announcement, the company and intermediaries still need to further verify and improve the response content. In order to ensure the authenticity, accuracy and completeness of the response content, the company will postpone the reply to the inquiry letter after applying to the Shanghai Stock Exchange, and the extension time will not exceed 5 trading days. We apologize for any inconvenience this may cause to investors.
The company will continue to actively promote the response work, organize all parties to complete the response to the inquiry letter as soon as possible and perform the information disclosure obligations in a timely manner. Investors are advised to refer to the information published in the company's designated information disclosure media and the Shanghai Stock Exchange website (www.sse.com.cn). Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
March 25, 2026